Capricor Therapeutics (CAPR) Accumulated Depreciation (2012 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Accumulated Depreciation of $5.6 million for Q1 2026, up 53.76% year-over-year from $3.7 million in Q1 2025, and up 9.6% quarter-over-quarter from $5.2 million in Q4 2025.
Capricor Therapeutics (CAPR) Accumulated Depreciation (2012 - 2026) Analysis & Trends
Capricor Therapeutics' Accumulated Depreciation history runs 12 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Accumulated Depreciation rose 53.76% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (up 53.76% YoY), while the FY2025 annual figure was $5.2 million, up 49.29% from the prior year.
- Accumulated Depreciation for Q1 2026 stood at $5.6 million, up from $5.2 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $5.6 million in Q1 2026, with the low at $830565.0 in Q1 2022.
- The 5-year median for Accumulated Depreciation is $2.5 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation grew 8.2% in 2022, then surged 86.7% in 2023.
- Capricor Therapeutics' Accumulated Depreciation stood at $1.2 million in 2022, then soared by 86.7% to $2.2 million in 2023, then surged by 56.39% to $3.5 million in 2024, then soared by 49.29% to $5.2 million in 2025, then advanced by 9.6% to $5.6 million in 2026.
- Business Quant data shows CAPR's Accumulated Depreciation at $5.6 million in Q1 2026, $5.2 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.65 Mn |
| Dec 31, 2025 | 5.15 Mn |
| Sep 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.16 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | 2.21 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 942,576.00 |
| Mar 31, 2022 | 830,565.00 |
| Dec 31, 2021 | 756,712.00 |
| Sep 30, 2021 | 883,467.00 |
| Jun 30, 2021 | 818,747.00 |